Abstract-Reports on the effectiveness of endothelin receptor blockers in angiotensin (Ang) II-induced end-organ damage are conflicting, and the mechanisms involved are uncertain. We tested the hypothesis that endothelin (ET) A/B receptor blockade with bosentan (100 mg/kg by gavage after age 4 weeks) ameliorates cardiac and renal damage by decreasing inflammation in rats harboring both human renin and angiotensinogen genes (dTGR). Furthermore, we elucidated the effect of bosentan on tissue factor (TF), which is a key regulator of the extrinsic coagulation cascade. We compared bosentan with hydralazine (80 mg/L in the drinking water for 3 weeks) as a blood pressure control. Untreated dTGR featured hypertension, focal necrosis in heart and kidney, and a 45% mortality rate (9 of 20) at age 7 weeks. Compared with Sprague-Dawley controls, both systolic blood pressure and 24-hour albuminuria were increased in untreated dTGR (203Ϯ8 versus 111Ϯ2 mm Hg and 67.1Ϯ8.6 versus 0.3Ϯ0.06 mg/d at week 7, respectively). Bosentan and hydralazine both reduced blood pressure and cardiac hypertrophy. Mortality rate was markedly reduced by bosentan (1/15) and partially by hydralazine (4/15). However, only bosentan decreased albuminuria and renal injury. Untreated and hydralazine-treated dTGR showed increased nuclear factor (NF)-B and AP-1 expression in the kidney and heart; the p65 NF-B subunit was increased in the endothelium, vascular smooth muscles cells, infiltrating cells, glomeruli, and tubules. In the heart and kidney, ET A/B receptor blockade inhibited NF-B and AP-1 activation compared with hydralazine treatment. Macrophage infiltration, ICAM-1 expression, and the integrin expression on infiltrating cells were markedly reduced. Renal vasculopathy was accompanied by increased tissue factor expression on macrophages and vessels of untreated and hydralazine-treated dTGR, which was markedly reduced by bosentan. Thus, ET A/B receptor blockade inhibits NF-B and AP-1 activation and the NF-B-and/or AP-1-regulated genes ICAM-1, VCAM-1, and TF, independent of blood pressure-related effects. We conclude that Ang II-induced NF-B and AP-1 activation and subsequent inflammation and coagulation involve at least in part the ET A/B receptors. (Hypertension. 2000;36:282-290.)
T he development and progression of malignant, hypertension-induced, end-organ damage is incompletely understood; however, vascular inflammatory responses, extracellular matrix protein accumulation, and thrombosis in small vessels are all involved. [1] [2] [3] Angiotensin (Ang) II, the key effector of the local and circulating renin-angiotensin system, plays a central role. 3, 4 Recently, Ang II was shown to be a powerful stimulator of endothelin (ET-1) synthesis and release in vascular smooth muscle and endothelial cells. [5] [6] [7] [8] Furthermore, Ang II-induced tissue ET-1 fosters vascular hypertrophy. 9, 10 The importance of ET-1 in cardiovascular disease has recently been reviewed. 11 Ang II can activate the nuclear transcription factor NF-B. NF-B is primarily responsible for the transcription of MCP-1 and adhesion molecules, 12, 13 leading to inflammation. NF-B also regulates the transcription of tissue factor (TF). TF initiates the extrinsic coagulation through an enzymatic factor VII/ factor VIIa complex formation. Constitutive TF expression by mesenchymal cells in the adventitial blood vessel lining normally precludes TF interaction with factor VII in plasma but allows activation of coagulation when the endothelium is damaged. 14 TF plays an important role in cardiovascular diseases but also has biological functions independent of the clotting cascade. [15] [16] [17] [18] [19] Rats harboring both human renin and angiotensinogen genes (dTGR) develop hypertension and severe renal and cardiac damage. 20, 21 NF-B activation, MCP-1 production, adhesion molecule expression, and inflammation are prominent features in the damaged kidneys of dTGR. 21, 22 We provide evidence that bosentan inhibits Ang II-induced NF-B and AP-1 activation, prevents inflammation, and ameliorates end-organ damage. We show that ET A/B receptor blockade decreases TF expression in Ang II-induced vasculopathy, which may ameliorate the microthrombosis featured in this model.
Methods
Four-week-old male age-matched and body weight-matched dTGR and Sprague Dawley (SD) rats were used as described elsewhere. 20 All procedures were done according to guidelines from the American Physiological Society. We compared untreated dTGR (nϭ20), bosentan-treated (100 mg/kg for 3 weeks by gavage once a day; nϭ15), hydralazine-treated dTGR (80 mg/L in the drinking water for 3 weeks; nϭ15), and SD control rats (nϭ10) receiving vehicle (1% sodium carboxymethylcellulose). This bosentan dosage produces a maximal pharmacological effect in rats. 23 Systolic blood pressure was measured at weeks 6 and 7 by the tail-cuff method under light ether anesthesia 20 hours after the last drug dose. Urine was collected over a 24-hour period. Rats were killed at age 7 weeks. The kidneys and hearts were washed with ice cold saline, blotted dry, and weighed. For Western blot and NF-B analysis, the tissues were snap-frozen in liquid nitrogen, for immunohistochemistry in isopentane (Ϫ35°C), and stored at Ϫ80°C.
Tissue preparation and immunohistological techniques were performed as described before in detail. 24 The sections were incubated with primary monoclonal antibodies against rat monocytes/macrophages (ED-1, Serotec), NF-B subunit p65 (Roche Boehringer), ICAM-1 (1A29, R&D Systems), LFA-1 (WT.1, Pharmingen), VLA-4 (TA-4, Pharmingen), and with polyclonal antibodies against TF (gift of Dr Th. Luther, TU Dresden, Germany), PAI-1 (American Diagnostica), and fibronectin (Paesel-Lorei). Scoring of ED-1-, LFA-1-, and VLA-4 -positive cells was performed with the use of the program KS 300 3.0 (Zeiss). Fifteen different areas of each heart and kidney (nϭ4 to 5 in all groups) were analyzed without knowledge of rat identity. Urinary ET-1 concentration was determined by radioimmunoassay as described previously. 25 Quantitative determination of albumin concentration in the urine was performed with the use of a commercially available rat albumin ELISA kit (Celltrend). Urinary ET-1 concentrations were normalized to urinary creatinine concentrations.
Tissue preparation for electrophoretic mobility shift assay (EMSA) was performed as described before in detail. 24 Total tissue homogenates were incubated in a binding reaction medium with 0.5 ng of 32 P-dATP end-labeled oligonucleotide, containing the NF-B binding site from the MHC enhancer (H2K, 5Ј-gatc-CAGGGCTGGGGATTCCCCATCTCCACAGG). For AP-1, double-stranded oligonucleotides containing the consensus sequence for AP-1 (Santa Cruz, 5Ј-GAT CGA ACT GAC CGC CCG CCG CCC GT-3Ј) were radiolabeled with ␥-32 P with the use of T4 polynucleotide kinase by standard methods and purified over a column. The DNA-protein complexes were analyzed on a 5% polyacrylamide gel, 0.5% Tris buffer, dried, and autoradiographed. In competition assays, 50 ng unlabeled H2K or AP-1 oligonucleo- 
Results
The renal tubules were swollen and filled with proteinaceous material in untreated dTGR. Renal and cardiac vessels showed increased intimal and medial thickness as well as microthrombi. Bosentan prevented vasculopathy and extracellular matrix formation. In contrast, hydralazine-treated sections appeared similar to untreated dTGR (data not shown). Nine (45%) of 20 untreated dTGR died at 7 weeks, whereas only 1 (7%) of 20 of the bosentan-treated and 4 (26%) of 15 hydralazine-treated rats died before the end of the study. Urinary ET-1 levels were significantly increased by 50% in untreated dTGR compared with SD rats, respectively (989Ϯ52 versus 646Ϯ50 pg ET-1/mg creatinine by week 7). Untreated dTGR, bosentan-treated dTGR, and hydralazinetreated dTGR were hypertensive at weeks 6 and 7 compared with SD ( Figure 1A ). Bosentan and hydralazine decreased blood pressure ( Figure 1A ) and cardiac weights (expressed as mg/g body wt) ( Figure 1B ). Body weight was not significantly different between the groups. Albuminuria ( Figure 1C ) was significantly reduced with bosentan but not with hydralazine.
We next investigated transcription factor activation influencing VCAM-1, ICAM-1, and TF gene expression. EMSA for the detection of NF-B showed a greater DNA binding activity in the kidneys of untreated dTGR compared with bosentan-treated or SD controls (Figure 2A ). On the other hand, hydralazine-treated dTGR were not distinguishable from untreated dTGR with respect to NF-B activity. Thus, bosentan treatment reduced levels of NF-B in kidney and heart (heart data not shown). Binding specificity was demonstrated by competition of excess unlabeled oligonucleotides containing the B site from the MHC enhancer (H2K) ( Figure 2B ). Semiquantification is given in Figure 2C . Western blot analysis showed reduced levels of I-B␣ in untreated and hydralazine-treated dTGR kidney ( Figure 2D ), whereas bosentan ameliorated I-B␣ reduction. Bosentan but not hydralazine also decreased AP-1 DNA binding activity in heart ( Figure 2E ) and kidney (kidney data not shown). Binding specificity ( Figure 2F ) and semiquantification (Figure 2G ) corroborated the results.
Immunohistochemical analysis (phase-contrast resolution) shows the localization of the subunit p65 of NF-B in the kidney (Figure 3 ). The expression of p65 was increased in the endothelium ( Figure 3A) , smooth muscle cells of small vessels ( Figure 3A) , glomeruli ( Figure 3B ), infiltrating cells ( Figure 3 , A through C), and tubules ( Figure 3C ) of untreated dTGR. No immunoreaction was observed in nontransgenic SD rats (Figure 3, D through F) . The NF-B activity in the kidney was markedly reduced by bosentan compared with untreated or hydralazine-treated dTGR (Figure 4 , A through D). We next investigated TF, which also contains B and AP-1 binding sites in the promoter. Untreated and hydralazine-treated dTGR showed an increased TF expression (Figure 4 , E through H), which resembles the localization of p65 in the vessel wall. Bosentan markedly reduced TF expression. VCAM-1 ( Figure 5 , A through D) and ICAM-1 ( Figure 5 , E through H) expression in dTGR kidneys and hearts (data not shown) was increased in the intima, whereas ICAM-1 was also increased in adventitia, glomeruli, tubules, and in the peritubular space. ICAM-1 and VCAM-1 expression was reduced by ET A/B receptor blockade but not by hydralazine. However, bosentan was more effective in the kidney than in the heart.
Immunohistochemical analysis of the integrins VLA-4 and LFA-1 in the kidney of untreated and hydralazine-treated dTGR showed increased expression in the perivascular space and adventitia. The semiquantification of the counterreceptors for VCAM-1 and ICAM-1 ( Figure 6 ) showed that bosentan reduced VLA-4 by 60% ( Figure 6A ) and LFA-1 by 70% ( Figure 6B ) in the kidney compared with untreated dTGR, respectively. There was significant perivascular monocyte/macrophage infiltration in the kidney and heart of untreated dTGR. Cell count analysis ( Figure 6C ) showed a 
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significant reduction in the mononuclear cell infiltration after bosentan treatment in kidney and heart compared with the hydralazine-treated and untreated dTGR (heart data not shown). The monocyte recruitment in the vascular wall was accompanied by increased PAI-1 expression (data not shown) in the same areas and accumulation of extracellular matrix protein. Fibronectin (Figure 7 , A through D) was completely reduced in the kidney and moderately reduced in the heart by bosentan treatment compared with untreated and hydralazinetreated dTGR ( Figure 7 , E through H).
Discussion
We tested the hypothesis that bosentan treatment inhibits NF-B activation, prevents inflammatory responses, and Representative photomicrographs of adhesion molecules VCAM-1 (A through D) and ICAM-1 (E through H) in kidneys of dTGR, bosentan (BOS)-treated dTGR, hydralazine (HYD)-treated dTGR, and SD rats, respectively. VCAM-1 and ICAM-1 expression of dTGR was increased in intima, whereas ICAM-1 was also increased in adventitia, glomeruli, tubules, and peritubular space. VCAM-1 and ICAM-1 were reduced only with bosentan treatment but not with hydralazine.
ameliorates Ang II-induced cardiac and renal damage. Furthermore, we investigated the effect of bosentan on TF, which is the major initiator of the coagulation pathway in vivo. 17 Our animal model features hypertension, vasculopathy, severe renal damage, cardiac hypertrophy, inflammation, focal necrosis in heart and kidney, and a 45% mortality rate at 7 weeks. 20, 21 We found that bosentan but not hydralazine ameliorated end-organ damage. Both drugs decreased blood pressure and cardiac hypertrophy slightly; however, albuminuria was only reduced after ET A/B receptor blockade. We recently showed that Ang II-independent treatment with hydralazine, reserpine, and hydrochlorothiazide to normotensive levels merely delayed organ damage and inflammation in dTGR. 26 That study demonstrated that Ang II-independent normalization of blood pressure reduced cardiac hypertrophy to a minor extent. In contrast, a human specific renin inhibitor, which was only partially active on blood pressure, led to a significant reduction in cardiac hypertrophy, compared with triple therapy. 26 By using Tsukuba mice overexpressing the human renin and angiotensinogen genes, Kai et al 23 showed that a blood pressure reduction with hydralazine did not prevent cardiac hypertrophy and nephropathy.
In the present study, hydralazine treatment resulted in a slight but significant reduction in cardiac hypertrophy. However, hydralazine did not decrease AP-1 DNA binding activity and extracellular matrix formation in heart and kidney. We speculate that the reduction in cardiac hypertrophy by hydralazine may be overestimated because 26% of hydralazinetreated rats died before the end of the study. Autopsies of all hydralazine rats, which were not included in the cardiac hypertrophy index, showed enlarged hearts. In addition, Ang II is known to stimulate immediate early genes, cell proliferation, and hypertrophic responses. [27] [28] [29] Recently, 2 groups showed that Ang II induced c-fos, c-jun, and AP-1 activity in vascular smooth muscle cells. 27, 28 Bosentan was able the reduce AP-1 DNA binding activity and AP-1 regulated fibronectin formation in the heart. Thus, reduction of cardiac hypertrophy by bosentan may be partially mediated by AP-1. In contrast, bosentan reduced blood pressure only to Ϸ165 mm Hg. Therefore, mechanical load may have counterregulated the reduction of hypertrophy. Altogether, treatment with bosentan also ameliorated cardiac vasculopathy and fibrosis as well as inflammation.
Ang II is a powerful stimulator of ET-1 in vascular smooth muscle and endothelial cells. [5] [6] [7] Tissue ET-1 induced by Ang II is known to induce vascular hypertrophy. 9, 10 However, reports on the effectiveness of ET-1 receptor blockers in Ang II-induced end-organ damage are conflicting. 30 -32 Herizi et al 31 showed that bosentan ameliorated end-organ damage in Ang II-infused rats. We were thus not surprised to find that bosentan ameliorated the severity of vascular damage in dTGR. Recently, Randolph et al 30 showed reduced left ventricular hypertrophy as well as ␤-myosin heavy chain and ANP gene expression in the early phase of renovascular hypertension after ET A receptor blockade, independent of blood pressure. In contrast, Li et al 32 were not able to show beneficial effects of bosentan in 2-kidney 1-clip renovascular hypertensive rats. However, Li et al 32 used rats that had already developed hypertension and presumably already had end-organ damage. Thus, they studied disease regression. In addition, the late phase of 2-kidney 1-clip hypertension may be less dependent on high Ang II levels.
We sought to elucidate molecular mechanisms involved in the pathogenesis of end-organ damage in dTGR and the possible role of endothelin as a mediator. Several reports have demonstrated the participation of macrophages in the onset and progression of various kidney diseases. 33, 34 Cell surface adhesion molecules could play a major role in mediating cell recruitment. NF-B, the main factor in the transcription of VCAM-1 and ICAM-1, plays an important role in various cardiovascular diseases. Several studies have shown that NF-B plays an important role in cardiac and renal end-organ damage. Zhang et al 35 have shown that ACE inhibition decreased NF-B in kidneys with ureteral obstruction. RuizOrtega et al 13 have reported that NF-B and MCP-1 activation in the renal cortex was reduced by ACE inhibition in experimental immune complex nephritis. They also showed that Ang II stimulated NF-B and MCP-1 in mesangial cells. Morishita et al 36 showed that NF-B inhibition by a decoy technique reduced the extent of myocardial infarction after reperfusion. End-organ damage in dTGR was accompanied by the activation of NF-B and AP-1 in both the kidney and heart. However, Ang II-induced inflammatory response, vasculopathy, and the induction of the various NF-Band/or AP-1-regulated genes was more prominent in the kidney compared with the heart. Bosentan ameliorated renal and cardiac damage; however, renal protection was more efficient. Recently, we showed that the unselective NF-B inhibitor PDTC reduced albuminuria by Ͼ90%. 24 However, PDTC reduced blood pressure, inflammation, cardiac vasculopathy, and cardiac hypertrophy similar to bosentan. Thus, NF-B plays a role in both cardiac and renal damage. Remuzzi and Bertani 37 have shown that filtered albumin is able to activate NF-B. They demonstrated that increased glomerular permeability is followed by increased filtration of macromolecules, followed by excessive tubular protein reabsorption. 37, 38 This process leads to abnormal accumulation of proteins in endolysosomes and endoplasmic reticulum. Altogether, these processes foster the activation of NF-B- dependent and NF-B-independent cytokines, resulting in renal inflammation. Inhibition of NF-B by bosentan treatment may have inhibited both the direct activation of NF-B by Ang II as well as the subsequent activation induced by the increased glomerular permeability in our model, thereby breaking the self-amplifying loop. Thus, NF-B inhibition may be an additional mechanism that might further explain the anti-inflammatory effects of ET-1 receptor blockers in progressive kidney disease.
TF plays an important role in vasculopathies, reperfusion injury, preeclampsia, and kidney disease. [15] [16] [17] [18] 39 Ang II stimulates TF. 15, 40 TF expression in dTGR was predominantly located in the walls of damaged vessels, which also stained positive for p65. Integrin-matrix signaling is also known to play an important role in inflammation and coagulation 41 The Ang II-induced formation of fibronectin in the kidney and heart was reduced by bosentan treatment, an effect that could have mechanistic implications. Several reports suggest that the ␤ 1 integrin VLA-4 induces monocyte procoagulant activity. 42, 43 McGilvray et al 42 showed that the VLA-4 integrin cross-linked on human monocytes induces TF expression by a mechanism involving mitogen-activated protein kinase. We found marked infiltration of VLA-4 -positive cells in dTGR kidneys, which was reduced after ET A/B receptor blockade. Thus, it is tempting to speculate that VLA-4/fibronectin signaling also stimulates TF expression in our model. Recently, Giesen et al 18 and Nemerson and Giesen 19 showed that in addition to the scheme whereby coagulation is initiated after vessel damage and blood exposure to vessel wall-bound TF, leukocytes are the main source of blood-borne TF. dTGR showed both vessel wall damage and leukocyte activation, which may both have influenced TF activity.
In summary, we showed that bosentan decreased blood pressure and cardiac hypertrophy and provided considerable renal protection in Ang II-induced end-organ damage. Vascular injury was largely prevented, and mortality rate was reduced. The amelioration of renal damage was provided by ET A/B receptor blockade, since hydralazine treatment was not effective. We provide evidence that long-term ET A/B receptor blockade in vivo inhibits renal NF-B activation and TF expression in Ang II-induced vasculopathy. Bosentan also markedly reduces the expression of NF-B-regulated genes such as VCAM-1 and ICAM-1 and thereby diminishes monocyte infiltration. These findings suggest that ET A/B receptor blockade may provide an anti-inflammatory and antithrombotic effect that could extend to other kidney diseases.
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